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Background
Kaposi sarcoma (KS) is commonly staged using by the
AIDS Clinical Trials Group (ACTG) criteria. The three
variables of the ACTG are dichotomized as good risk
(0) and poor risk (1). Good risk immune status (I0) is
defined as CD4 T-cell count ≥200cells/µl, and poor risk
(I1) as CD4 < 200cells/µl. Although validated in the US
and Europe, no evaluation has been done in resource-
limited settings during the HAART era. We sought to
determine whether the ACTG staging criteria is predic-
tive of overall survival among Ugandan patients with
HIV-associated KS.
Methods
Data were abstracted from medical records of adult
patients with HIV-associated KS seen at the Uganda
Cancer Institute (UCI) from 2000-2006. The primary
outcome was 2-year overall survival. Vital status at
2 years was determined from the medical chart, or by
contacting the patient or next of kin using the phone
contact provided in the chart or ART clinic. Survival
was modeled using Kaplan-Meier methods. Factors asso-
ciated with survival were evaluated using Cox propor-
tional hazards.
Results
The median survival time was 468 days (range 0, 5411).
At 2 years following KS diagnosis, 165 (40.8%) of parti-
cipants were alive and 166 (41.1%) had died, while
73(18.1%) were lost to follow-up. Factors associated with
death before 2 years from KS diagnosis included T1
tumor stage, S1 stage, nodular lesion morphotype, and
trunk edema (Table 1). Baseline CD4 count under
100 cells/µl was associated with decreased survival (HR
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Table 1 Factors associated with death before 2 years from KS diagnosis
Univariate Multivariate
FACTOR HR 95% CI P-value HR 95% CI P-value
T1 VS T0 4.13 2.18-7.81 <0.001 4.33 2.36-8.77 <0.001
I1 VS I0 1.25 0.64-2.44 0.52 …….. ………… ………..
S1 VS S0 1.71 1.13-2.57 0.01 1.69 1.12-2.53 <0.01
Age (yrs) 0.98 0.96-1.00 0.05 0.98 0.96-1.00 0.01
Nodular KS morphotype 1.50 0.97-2.32 0.07 1.34 0.84-2.15 0.22
Trunk edema 2.91 1.53-5.53 <0.001 2.45 1.27-4.75 0.01
On HAART at diagnosis 0.75 0.54-1.02 0.07 0.62 0.45-0.87 0.01
Receipt of chemotherapy 0.46 0.33-0.65 <0.001 0.29 0.20-0.42 <0.001
* Multivariate analysis adjusted for T, S, age, nodular morphotype, trunk edema, HAART, and chemotherapy.
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status criteria (CD4 under 200 cells/µl) was not.
Conclusions
ACTG criteria Tumor extent (T) and Systemic symp-
toms (S) were associated with survival; Immune status
(I) was not. Factors associated with decreased survival
included: baseline CD4 counts <100, age, trunk edema,
while receipt of HAART and chemotherapy were asso-
ciated with increased survival. Studies are needed to
validate ACTG staging criteria in sub-Saharan Africa
and to identify additional prognostic factors.
Author details
1Uganda Cancer Institute, Kampala, Uganda.
2Department of Medicine,
Makerere University, College of Health Sciences, Kampala, Uganda.
3Department of Medicine, University of Washington, Seattle, WA, USA.
4Laboratory Medicine, University of Washington, Seattle, WA, USA.
5Epidemiology, University of Washington, Seattle, WA, USA.
6Global Health,
University of Washington, Seattle, WA, USA.
7Vaccine and Infectious Disease
Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Published: 19 April 2012
doi:10.1186/1750-9378-7-S1-P8
Cite this article as: Okuku et al.: Evaluation of the AIDS clinical trials
group staging criteria for Kaposi Sarcoma in a resource limited setting.
Infectious Agents and Cancer 2012 7(Suppl 1):P8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Okuku et al. Infectious Agents and Cancer 2012, 7(Suppl 1):P8
http://www.infectagentscancer.com/content/7/S1/P8
Page 2 of 2